The findings of two separate studies further substantiate that treatment with the investigational ultra rapid acting mealtime insulin AFREZZA� (insulin human [rDNA origin]) Inhalation Powder does not result in excess cardiovascular events in type 1 or type 2 diabetes patients. Furthermore, results demonstrate that inhaled AFREZZA did not produce clinically significant effects on heart rate, PR and QRS interval duration, or cardiac morphology. The data are being presented at the American Diabetes Association's 71st Scientific Sessions�...
No comments:
Post a Comment